Functional Gastrointestinal Disorders: Complex Treatments for Complex Pathophysiological Mechanisms

No matter which country in the World is evaluated, the prevalence of functional gastrointestinal disorders (FGID) is very high. In fact, this is the most frequent cause of gastroenterological consultation. Nevertheless, many patients suffering from FGID never ask for medical assistance, so what physicians see is probably only the tip of the iceberg. FGID have a significant impact on patients’ everyday activities and quality of life, inducing emotional distress because of their chronic symptoms. Moreover, disorders such as functional dyspepsia (FD) and irritable bowel syndrome (IBS) result in heavy economic burdens through direct medical expenses and loss of productivity. Like other diseases that disturb life’s activities, IBS is accompanied by a sphere of biopsychosocial implications. The WHO introduced the concepts of disability, impairment, and handicap to accurately define the impact of diseases on quality of life so that the different designed scales reflect all aspects of life restrictions caused by diseases. Impairment is defined as the signs and symptoms that are a direct consequence of the disease [1]. Disability is the boundary or the loss of ability to perform activities that would be considered normal for a human being (limitations of daily activities caused by a disease). Handicap represents the effects of disease in terms of avoiding patients’ development in a social structure (social and environmental limitations because of disease). The impact of FD and IBS include every aspect of life (sleep, sexual activity, diet, work, etc.), and therefore there is a significant disability, impairment, and handicap.

[1]  M. Storr,et al.  Evaluating the Multitarget Effects of Combinations through Multistep Clustering of Pharmacological Data: the Example of the Commercial Preparation Iberogast , 2017, Planta Medica.

[2]  D. Drossman Functional Gastrointestinal Disorders: History, Pathophysiology, Clinical Features and Rome IV. , 2016, Gastroenterology.

[3]  Jan Tack,et al.  Gastroduodenal Disorders. , 2016, Gastroenterology.

[4]  P. Malfertheiner,et al.  STW 5 (Iberogast®)—a safe and effective standard in the treatment of functional gastrointestinal disorders , 2012, Wiener Medizinische Wochenschrift.

[5]  A. Ford,et al.  Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. , 2012, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.

[6]  O. Kelber,et al.  STW 5 is effective in dextran sulfate sodium-induced colitis in rats , 2012, International Journal of Colorectal Disease.

[7]  G. L. Engel The need for a new medical model: a challenge for biomedicine. , 2012, Psychodynamic psychiatry.

[8]  S. Hauschildt,et al.  Inhibition of inflammation-induced alterations in rat small intestine by the herbal preparations STW 5 and STW 6. , 2009, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[9]  Karen L Jones,et al.  Effects of Iberogast® on Proximal Gastric Volume, Antropyloroduodenal Motility and Gastric Emptying in Healthy Men , 2007, The American Journal of Gastroenterology.

[10]  M. Schemann,et al.  Region-specific effects of STW 5 (Iberogast) and its components in gastric fundus, corpus and antrum. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[11]  S. Klement,et al.  A combination of valerian and lemon balm is effective in the treatment of restlessness and dyssomnia in children. , 2006, Phytomedicine : international journal of phytotherapy and phytopharmacology.

[12]  K. Goh,et al.  Epidemiology of functional dyspepsia: a global perspective. , 2006, World journal of gastroenterology.

[13]  R. Saller,et al.  Meta‐analysis: phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast) , 2004, Alimentary pharmacology & therapeutics.

[14]  G. Holtmann,et al.  Treatment of irritable bowel syndrome with herbal preparations: results of a double‐blind, randomized, placebo‐controlled, multi‐centre trial , 2004, Alimentary pharmacology & therapeutics.

[15]  E. Ernst,et al.  Herbal medicinal products for non‐ulcer dyspepsia , 2002, Alimentary pharmacology & therapeutics.

[16]  D. Drossman Gastrointestinal Illness and the Biopsychosocial Model , 1998, Psychosomatic medicine.

[17]  Y. Katayama Bowel disorders. , 1990, Postgraduate medicine.